7/102 sources · 2 publishersUpdated Oct 13, 11:42 UTC
Genmab reports $4.24 billion Q3 2026 DARZALEX sales, up 15% YoY
Genmab announced that DARZALEX generated net sales of $4.24 billion in the third quarter of 2026, of which $2.53 billion came from the United States and $1.71 billion from the rest of the world. The sales represent a 15% year‑over‑year increase from $3.67 billion in Q3 2025. Genmab receives royalty payments on these sales, which are a core source of its revenue.
Why it matters
The company expects the higher DARZALEX sales to boost its royalty income and overall cash flow, according to the earnings release. Analysts note that the growth may improve Genmab’s earnings outlook for the year.
Key facts
- 1DARZALEX net sales were $4.24 billion in Q3 2026. tradingview.com
- 2U.S. sales accounted for $2.53 billion of the total. tradingview.com
- 3International sales (rest of world) were $1.71 billion. tradingview.com
- 4Sales were up 15% year‑over‑year from $3.67 billion in Q3 2025. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.